We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Notch inhibition overcomes resistance to tyrosine kinase inhibitors in EGFR-driven lung adenocarcinoma.
- Authors
Bousquet Mur, Emilie; Bernardo, Sara; Papon, Laura; Mancini, Maicol; Fabbrizio, Eric; Goussard, Marion; Ferrer, Irene; Giry, Anais; Quantin, Xavier; Pujol, Jean-Louis; Calvayrac, Olivier; Moll, Herwig P.; Glasson, Yaël; Pirot, Nelly; Turtoi, Andrei; Cañamero, Marta; Kwok-Kin Wong; Yarden, Yosef; Casanova, Emilio; Soria, Jean-Charles
- Abstract
EGFR-mutated lung adenocarcinoma patients treated with gefitinib and osimertinib show a therapeutic benefit limited by the appearance of secondary mutations, such as EGFRT790M and EGFRC797S. It is generally assumed that these secondary mutations render EGFR completely unresponsive to the inhibitors, but contrary to this, we uncovered here that gefitinib and osimertinib increased STAT3 phosphorylation (p-STAT3) in EGFRT790M and EGFRC797S tumoral cells. Interestingly, we also found that concomitant Notch inhibition with gefitinib or osimertinib treatment induced a p-STAT3-dependent strong reduction in the levels of the transcriptional repressor HES1. Importantly, we showed that tyrosine kinase inhibitor-resistant tumors, with EGFRT790M and EGFRC797S mutations, were highly responsive to the combined treatment of Notch inhibitors with gefitinib or osimertinib, respectively. Finally, in patients with EGFR mutations treated with tyrosine kinase inhibitors, HES1 protein levels increased during relapse and correlated with shorter progression-free survival. Therefore, our results offer a proof of concept for an alternative treatment to chemotherapy in lung adenocarcinoma osimertinib-treated patients after disease progression.
- Subjects
PROTEIN-tyrosine kinases; KINASE inhibitors; LUNGS; ADENOCARCINOMA; PROGRESSION-free survival
- Publication
Journal of Clinical Investigation, 2020, Vol 130, Issue 2, p612
- ISSN
0021-9738
- Publication type
journal article
- DOI
10.1172/JCI126896